Abstract | BACKGROUND: PATIENTS AND METHODS: Analysis included 446 consecutive patients treated with platinum-based chemotherapy for advanced or metastatic urothelial cancer. There were 389 (87%) patients with pure TCC, 15 (3.5%) with pure Squamous Cell Carcinomas (SCC) and 42 (9.5%) patients had mixed histology (TCC+SCC) tumors. RESULTS: There were no statistically significant differences in baseline characteristics (gender, PS, haemoglobin, sites of metastases) although disease in the pelvis was more frequent in mixed tumors than in pure TCCs (46% vs. 30%, p = 0.034). Median survival for patients with TCC histology was 11.3 months, for SCC patients 13.6 months and 10.4 months for patients with mixed histology (p = 0.720). Response rates were 44% for patients with TCC, 27% for patients with SCC and 34% for mixed histology patients (p = 0.210). Multivariate analysis showed that presence of visceral metastases and poor performance status, were associated with worse prognosis in mixed histology tumors. CONCLUSION:
|
Authors | Efstathios Kastritis, Meletios-Athanasios Dimopoulos, Nikolaos Antoniou, Charalambos Deliveliotis, Michael Chrisofos, Andreas Skolarikos, Dimitra Gika, Aristotle Bamias |
Journal | Anticancer research
(Anticancer Res)
2006 Sep-Oct
Vol. 26
Issue 5B
Pg. 3865-9
ISSN: 0250-7005 [Print] Greece |
PMID | 17094415
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy)
- Carcinoma, Transitional Cell
(drug therapy)
- Female
- Humans
- Male
- Organoplatinum Compounds
(administration & dosage)
- Urinary Bladder Neoplasms
(drug therapy)
|